Chiome Bioscience

Chiome Bioscience EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience (4583.T) as of Oct 21, 2026 is -56.72 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -41.75 % — a change of 35.83% (lower).

EBIT/Assets

-56.72 %

YoY

35.83%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience is 2025 -56.72 % . Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience was 2024 -41.75 % . It decreases by 35.83% lower compared to the previous year.

The Chiome Bioscience EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-54.36 JPY
Jan 1, 2019
-49.93 JPY
Jan 1, 2020
-36.73 JPY
Jan 1, 2021
-62.33 JPY
Jan 1, 2022
-56.81 JPY
Jan 1, 2023
-68.81 JPY
Jan 1, 2024
-41.75 JPY
Jan 1, 2025
-56.72 JPY
The Chiome Bioscience EBIT/Assets history
YEAREBIT/AssetsYoY
-56.72 %+35.83%
-41.75 %-39.32%
-68.81 %+21.12%
-56.81 %-8.85%
-62.33 %+69.69%
-36.73 %-26.43%
-49.93 %-8.16%
-54.36 %+170.60%
-20.09 %-7.70%
-21.76 %-15.70%
-25.82 %+39.98%
-18.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Chiome Bioscience Stock analysis

What does Chiome Bioscience do? Chiome Bioscience, Inc. operates in Shibuya-Ku, Tokyo-To and generates revenue through two distinct business segments focused on antibody drug development. The Drug Discovery segment conducts research and development of specific antibodies based on new antigens and mechanisms, subsequently licensing these assets to pharmaceutical companies. This approach allows the firm to monetize its proprietary technology and scientific findings directly through licensing agreements. The Drug Discovery Support segment complements this by developing lead antibodies for therapeutic drugs in collaboration with pharmaceutical companies in Japan and overseas. Through these partnerships, the company provides specialized development services that support the creation of new therapeutic agents. Both segments leverage the company's Autonomous Diversifying Library (ADLib) system to facilitate the creation and refinement of antibody drugs for its clients. Chiome Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chiome Bioscience stock

Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience is -56.72 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Chiome Bioscience changed from -41.75 % to -56.72 %, representing a 35.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Chiome Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Chiome Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Chiome Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Chiome Bioscience